Publications

Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile  (2010)

Authors:
Gatti L.; Perego P.; Leone R.; Apostoli P.; Carenini N.; Corna E.; Allievi C.; Bastrup U.; Munari S.D.; Giovine S.D.; Nicoli P.; Grugni M.; Natangelo M.; Pardi G.; Pezzoni G.; Singer J.W.; Zunino F.
Title:
Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile
Year:
2010
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Format:
A Stampa
Referee:
No
Name of journal:
MOLECULAR PHARMACEUTICS
ISSN of journal:
1543-8384
N° Volume:
7
Number or Folder:
1
Page numbers:
207-216
Keyword:
Bis-platinum complexes; antitumor efficacy; plasma binding; drug development
Short description of contents:
Multinuclear platinum complexes are characterized by a peculiar DNA binding mode and higher cytotoxic potency than the mononuclear complexes, and efficacy against a wide range of preclinical tumor models. To reduce the high irreversible plasma protein binding and improve the chemical and metabolic drug stability, novel bis-platinum complexes were designed starting from the parent compound CT-3610. The novel second-generation bis-platinum complexes utilize alkylcarboxylate as leaving groups to improve their pharmacokinetic and pharmacodynamic profiles, thus overcoming the limitations of the previously developed multinuclear compounds. The selected compounds [CT-47518 and CT-47463, respectively (bis-capronate) platinum and (bis-butyrate) platinum], have similar in vitro degradation kinetics in human and murine plasma and, above all, an increased stability when compared to CT-3610, particularly in human plasma. In addition, both compounds exhibited a marked cytotoxic potency as compared with cisplatin and oxaliplatin. Interestingly, they were capable of overcoming resistance mediated by DNA mismatch repair defects in different cellular models. The complexes showed marked antitumor efficacy in Pt-refractory tumor xenografts, with remarkable activity in terms of tumor growth inhibition and tumor growth delay. The improved stability profile in human plasma compared to early bis- and triplatinum complexes together with the marked activity in cellular systems as well as in in vivo models, make CT-47518 and CT-47463 attractive candidates for further development.
Web page:
http://pubs.acs.org/doi/abs/10.1021/mp900211j
Product ID:
53834
Handle IRIS:
11562/339729
Deposited On:
April 19, 2010
Last Modified:
December 4, 2019
Bibliographic citation:
Gatti L.; Perego P.; Leone R.; Apostoli P.; Carenini N.; Corna E.; Allievi C.; Bastrup U.; Munari S.D.; Giovine S.D.; Nicoli P.; Grugni M.; Natangelo M.; Pardi G.; Pezzoni G.; Singer J.W.; Zunino F., Novel Bis-platinum Complexes Endowed with an Improved Pharmacological Profile «MOLECULAR PHARMACEUTICS» , vol. 7 , n. 12010pp. 207-216

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

Related projects
Title Department Managers
<<back

Activities

Research facilities